III期-话题@MedSci

#III期#

681篇内容 | 2809人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1594767, encodeId=df451594e6712, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=美国**新冠疫苗临床试验揭盲，将开启终极3万人大规模III期试验, objectType=article, longId=197606, objectId=7ad819e606e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ad819e606e1, replyNumber=0, likeNumber=14, createdTime=2020-07-17, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ad819e606e1, moduleTitle=美国**新冠疫苗临床试验揭盲，将开启终极3万人大规模III期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ad819e606e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594766, encodeId=6e051594e66b9, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq治疗晚期卵巢癌，III期研究失败, objectType=article, longId=197518, objectId=29ba19e518a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29ba19e518a8, replyNumber=0, likeNumber=59, createdTime=2020-07-16, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29ba19e518a8, moduleTitle=罗氏的PD-L1单抗Tecentriq治疗晚期卵巢癌，III期研究失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29ba19e518a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594765, encodeId=544d1594e65d3, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=抗体药物偶联物Trodelvy显著改善三阴性乳腺癌患者的PFS：III期研究达到终点, objectType=article, longId=197187, objectId=f91619e187c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f91619e187c8, replyNumber=0, likeNumber=18, createdTime=2020-07-09, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f91619e187c8, moduleTitle=抗体药物偶联物Trodelvy显著改善三阴性乳腺癌患者的PFS：III期研究达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f91619e187c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594764, encodeId=32ae1594e6404, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Regeneron的双抗体鸡尾酒疗法预防新冠病毒COVID-19感染，进入III期研究阶段, objectType=article, longId=197185, objectId=861519e185ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=861519e185ee, replyNumber=0, likeNumber=58, createdTime=2020-07-09, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=861519e185ee, moduleTitle=Regeneron的双抗体鸡尾酒疗法预防新冠病毒COVID-19感染，进入III期研究阶段, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=861519e185ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594763, encodeId=ad571594e634a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=失眠新药daridorexant的全新III期研究数据, objectType=article, longId=197166, objectId=4ec319e1668c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ec319e1668c, replyNumber=0, likeNumber=60, createdTime=2020-07-08, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ec319e1668c, moduleTitle=失眠新药daridorexant的全新III期研究数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ec319e1668c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594762, encodeId=68de1594e6214, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=IL-6受体单抗Kevzara，治疗新冠病毒COVID-19的III期临床失败, objectType=article, longId=196982, objectId=867e19698235, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=867e19698235, replyNumber=0, likeNumber=53, createdTime=2020-07-04, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=867e19698235, moduleTitle=IL-6受体单抗Kevzara，治疗新冠病毒COVID-19的III期临床失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=867e19698235)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594761, encodeId=f8e51594e61b3, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=每周一次皮下注射C5补体抑制剂ULTOMIRIS，治疗阵发性睡眠性血红蛋白尿达到了III期临床终点, objectType=article, longId=196488, objectId=a16319648829, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a16319648829, replyNumber=0, likeNumber=97, createdTime=2020-06-27, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a16319648829, moduleTitle=每周一次皮下注射C5补体抑制剂ULTOMIRIS，治疗阵发性睡眠性血红蛋白尿达到了III期临床终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a16319648829)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594760, encodeId=7ac61594e60ce, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Relugolix治疗子宫内膜异位症疼痛：III期研究达到所有关键终点, objectType=article, longId=196391, objectId=06ff19639198, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06ff19639198, replyNumber=0, likeNumber=49, createdTime=2020-06-25, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06ff19639198, moduleTitle=Relugolix治疗子宫内膜异位症疼痛：III期研究达到所有关键终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06ff19639198)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594759, encodeId=7de71594e5920, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq，新辅助治疗三阴性乳腺癌III期成功, objectType=article, longId=196192, objectId=ea03196192c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea03196192c4, replyNumber=0, likeNumber=95, createdTime=2020-06-22, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea03196192c4, moduleTitle=罗氏的PD-L1单抗Tecentriq，新辅助治疗三阴性乳腺癌III期成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea03196192c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594758, encodeId=e80e1594e5853, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=艾伯维的JAK抑制剂Rinvoq，III期临床显示出治疗特应性皮炎的潜力, objectType=article, longId=196190, objectId=6f67196190f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f67196190f1, replyNumber=0, likeNumber=55, createdTime=2020-06-22, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f67196190f1, moduleTitle=艾伯维的JAK抑制剂Rinvoq，III期临床显示出治疗特应性皮炎的潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f67196190f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594757, encodeId=0dbd1594e57fe, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=III期临床试验证明：Dorzagliatin单药治疗2型糖尿病疗效确切, objectType=article, longId=196105, objectId=041919610548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=041919610548, replyNumber=0, likeNumber=59, createdTime=2020-06-20, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=041919610548, moduleTitle=III期临床试验证明：Dorzagliatin单药治疗2型糖尿病疗效确切, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=041919610548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594756, encodeId=f8251594e564e, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Med Sci Monit：长期强化生活方式干预可促进III期糖尿病肾病的改善, objectType=article, longId=195972, objectId=217e1959e212, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=217e1959e212, replyNumber=0, likeNumber=65, createdTime=2020-06-18, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=217e1959e212, moduleTitle=Med Sci Monit：长期强化生活方式干预可促进III期糖尿病肾病的改善, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=217e1959e212)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594755, encodeId=d5e21594e55db, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=关注罕见病“红细胞生成性原卟啉症及X连锁卟啉症”：已启动MT-7117全球III期临床试验, objectType=article, longId=195935, objectId=1c30195935d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c30195935d4, replyNumber=0, likeNumber=15, createdTime=2020-06-17, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c30195935d4, moduleTitle=关注罕见病“红细胞生成性原卟啉症及X连锁卟啉症”：已启动MT-7117全球III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c30195935d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594754, encodeId=8eb21594e5473, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=生物制剂CD24Fc治疗重症COVID-19：III期临床取得积极进展, objectType=article, longId=195933, objectId=588919593321, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=588919593321, replyNumber=0, likeNumber=52, createdTime=2020-06-17, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=588919593321, moduleTitle=生物制剂CD24Fc治疗重症COVID-19：III期临床取得积极进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=588919593321)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594753, encodeId=09ad1594e53c1, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=实验性生物制剂CD24Fc治疗重症COVID-19：III期临床取得积极进展, objectType=article, longId=195932, objectId=08a71959323d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08a71959323d, replyNumber=0, likeNumber=15, createdTime=2020-06-17, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08a71959323d, moduleTitle=实验性生物制剂CD24Fc治疗重症COVID-19：III期临床取得积极进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08a71959323d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594752, encodeId=46d71594e527d, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=EHA 2020：III期头对头研究证实C3补体抑制剂pegcetacoplan治疗阵发性夜间血红蛋白尿疗效显著, objectType=article, longId=195820, objectId=4ad419582055, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ad419582055, replyNumber=0, likeNumber=13, createdTime=2020-06-15, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ad419582055, moduleTitle=EHA 2020：III期头对头研究证实C3补体抑制剂pegcetacoplan治疗阵发性夜间血红蛋白尿疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ad419582055)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594751, encodeId=4c761594e5141, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=默克的PD-1单抗Keytruda联合化疗用于晚期尿路上皮癌，III期临床失败, objectType=article, longId=195619, objectId=fa0e195619b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa0e195619b6, replyNumber=0, likeNumber=84, createdTime=2020-06-12, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa0e195619b6, moduleTitle=默克的PD-1单抗Keytruda联合化疗用于晚期尿路上皮癌，III期临床失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa0e195619b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594750, encodeId=9c351594e5007, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=ERA-EDTA 2020：RNAi疗法公司Alnylam再发力！Lumasiran治疗1型原发性高草酸尿症III期临床成功, objectType=article, longId=195493, objectId=6fc619549390, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fc619549390, replyNumber=0, likeNumber=60, createdTime=2020-06-10, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fc619549390, moduleTitle=ERA-EDTA 2020：RNAi疗法公司Alnylam再发力！Lumasiran治疗1型原发性高草酸尿症III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fc619549390)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594749, encodeId=ad701594e49ce, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept, objectType=article, longId=195490, objectId=a38e195490b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a38e195490b9, replyNumber=0, likeNumber=13, createdTime=2020-06-10, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a38e195490b9, moduleTitle=EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a38e195490b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594748, encodeId=f7851594e48cc, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Lancet oncol：III期试验：ripretinib单药治疗晚期胃肠间质肿瘤的疗效和安全性, objectType=article, longId=195474, objectId=2d9e1954e445, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d9e1954e445, replyNumber=0, likeNumber=63, createdTime=2020-06-09, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d9e1954e445, moduleTitle=Lancet oncol：III期试验：ripretinib单药治疗晚期胃肠间质肿瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d9e1954e445)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III期

2020-05-29

智智灵药 (审核中...)

前往app查看评论内容

#III期#

美国**新冠疫苗临床试验揭盲，将开启终极3万人大规模III期试验

2020-07-17

智智灵药 (审核中...)

前往app查看评论内容

#III期#

罗氏的PD-L1单抗Tecentriq治疗晚期卵巢癌，III期研究失败

2020-07-16

智智灵药 (审核中...)

前往app查看评论内容

#III期#

抗体药物偶联物Trodelvy显著改善三阴性乳腺癌患者的PFS：III期研究达到终点

2020-07-09

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Regeneron的双抗体鸡尾酒疗法预防新冠病毒COVID-19感染，进入III期研究阶段

2020-07-09

智智灵药 (审核中...)

前往app查看评论内容

#III期#

失眠新药daridorexant的全新III期研究数据

2020-07-08

智智灵药 (审核中...)

前往app查看评论内容

#III期#

IL-6受体单抗Kevzara，治疗新冠病毒COVID-19的III期临床失败

2020-07-04

智智灵药 (审核中...)

前往app查看评论内容

#III期#

每周一次皮下注射C5补体抑制剂ULTOMIRIS，治疗阵发性睡眠性血红蛋白尿达到了III期临床终点

2020-06-27

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Relugolix治疗子宫内膜异位症疼痛：III期研究达到所有关键终点

2020-06-25

智智灵药 (审核中...)

前往app查看评论内容

#III期#

罗氏的PD-L1单抗Tecentriq，新辅助治疗三阴性乳腺癌III期成功

2020-06-22

智智灵药 (审核中...)

前往app查看评论内容

#III期#

艾伯维的JAK抑制剂Rinvoq，III期临床显示出治疗特应性皮炎的潜力

2020-06-22

智智灵药 (审核中...)

前往app查看评论内容

#III期#

III期临床试验证明：Dorzagliatin单药治疗2型糖尿病疗效确切

2020-06-20

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Med Sci Monit：长期强化生活方式干预可促进III期糖尿病肾病的改善

2020-06-18

智智灵药 (审核中...)

前往app查看评论内容

#III期#

关注罕见病“红细胞生成性原卟啉症及X连锁卟啉症”：已启动MT-7117全球III期临床试验

2020-06-17

智智灵药 (审核中...)

前往app查看评论内容

#III期#

生物制剂CD24Fc治疗重症COVID-19：III期临床取得积极进展

2020-06-17

智智灵药 (审核中...)

前往app查看评论内容

#III期#

实验性生物制剂CD24Fc治疗重症COVID-19：III期临床取得积极进展

2020-06-17

智智灵药 (审核中...)

前往app查看评论内容

#III期#

EHA 2020：III期头对头研究证实C3补体抑制剂pegcetacoplan治疗阵发性夜间血红蛋白尿疗效显著

2020-06-15

智智灵药 (审核中...)

前往app查看评论内容

#III期#

默克的PD-1单抗Keytruda联合化疗用于晚期尿路上皮癌，III期临床失败

2020-06-12

智智灵药 (审核中...)

前往app查看评论内容

#III期#

ERA-EDTA 2020：RNAi疗法公司Alnylam再发力！Lumasiran治疗1型原发性高草酸尿症III期临床成功

2020-06-10

智智灵药 (审核中...)

前往app查看评论内容

#III期#

EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept

2020-06-10

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Lancet oncol：III期试验：ripretinib单药治疗晚期胃肠间质肿瘤的疗效和安全性

2020-06-09

科室
- - 订阅+
  - 更多科室
工具
服务